ArticleHealth economics review2026
The economic burden of diabetes-related visual impairment and blindness in Saudi Arabia.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur main objective is to measure the economic impact of managing diabetes-related visual impairment and blindness in the Kingdom of Saudi Arabia (KSA) to inform policy and resource allocation for effective disease management and prevention.
methodsWe develop a prevalence-based cost of illness model using Microsoft Excel to assess the economic impact of treating diabetic-related visual impairment and blindness over a one-year period from societal perspective. The model categorizes costs according to the severity level of the condition: mild, moderate, and severe visual impairment and blindness. It encompasses direct medical expenses such as those for drug acquisitions, surgical procedures, healthcare resources, monitoring, visual aids, and psychological care, as well as indirect costs such as productivity losses in the financial year 2024. The model's outputs provide a cumulative and detailed breakdown of the costs associated with visual impairment and blindness in KSA. Sensitivity analysis was conducted.
resultsOur economic model shows that the total economic burden of diabetes-related visual impairment and blindness in KSA in one year is SAR 150,324,912,186 ($ 81.2 billion). This cost is divided into direct and indirect medical costs estimated at SAR 101 billion ($ 54.6 billion) and SAR 49 billion ($26.5 billion), respectively. The major component is medication costs, along with patients' productivity loss.
conclusionThe significant economic repercussions of diabetes-related visual impairment and blindness across individuals, households, and the Saudi healthcare system impose a substantial financial burden. These findings highlight the urgent need for investment in innovative interventions and screening programs aimed at mitigating these costs, enhancing accessibility to essential treatments, improving the quality of life of affected individuals and families, and achieving sustainable healthcare and socioeconomic development goals in the Kingdom.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.